Ultragenyx Pharmaceutical(US:RARE) Prnewswire·2026-02-06 13:49Core Viewpoint - The complaint against Ultragenyx alleges violations of federal securities laws due to misleading statements regarding the efficacy of setrusumab in treating Osteogenesis Imperfecta, particularly concerning the Phase III Orbit study results and the associated risks [2]. Group 1: Allegations and Misleading Information - The complaint claims that Ultragenyx and its executives created a false impression of having reliable information about setrusumab's effects on patients with Osteogenesis Imperfecta [2]. - It is alleged that Ultragenyx downplayed the risk that patients in the Phase III Orbit study would not achieve a statistically significant reduction in annualized fracture rate, which is critical for the study's interim analysis [2]. - The optimism expressed by Ultragenyx regarding the Phase III Orbit study's results is said to be misplaced, as the company failed to adequately disclose the risks associated with relying on Phase II results that lacked a placebo control group [2]. Group 2: Legal Proceedings and Class Action - The lead plaintiff in the class action is the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [3]. - Any member of the putative class has the option to move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [3]. Group 3: Whistleblower Encouragement - The law firm Faruqi & Faruqi encourages individuals with information regarding Ultragenyx's conduct, including whistleblowers and former employees, to come forward [4].